DUBLIN–(BUSINESS WIRE)–The “Global Decentralized Clinical Trial (DCT) Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering.
The report presents post-COVID-19 growth opportunities and strategic imperatives for the global decentralized clinical trials (DCT) market, covering the market’s maturity, key participants, adoption drivers and restraints, and recent mergers and acquisitions. It identifies initiatives by major global contract research organizations (CROs) toward DCT adoption; estimates growth patterns for the next 5 years based on detailed analyses of drug and biologics interventional trials, COVID-19-triggered adoption of DCT by sponsors and CROs to continue the disrupted trial operations; and the expected cost-benefit associated with the reduction in site-management burden. The analysis includes regional drivers and challenges of adoption based on select socio-economic and industry parameters.
The DCT market was in a nascent stage prior to the COVID-19 pandemic. The accelerated adoption witnessed during the pandemic outbreak in 2020 was mainly due to restricted mobility of site investigators, clinical research associates, and patients to participate in the trials. To ensure patient safety, most sponsors and CROs adopted digital tools to support trial operations that included telemedicine, remote source data verification, and sensor/mobile technology-enabled direct data-capture solutions. Recent initiatives conducted by the Decentralized Trials & Research Alliance have increased awareness of DCTs globally and catapulted their adoption, especially in North America. The evolving regulations supporting the ease of implementing technologies that enable DCT delivery in Europe and other regions will drive adoption.
However, adoption of decentralized trials is challenged by concerns about data privacy, scalability, and seamless implementation across different continents. Need has increased to support decentralized trials through cloud-based platform solutions that are fit to purpose. CROs building decentralized trial capabilities are partnering with technology vendors to overcome these challenges. Online training modules for patients and secure technology for at-home trial monitoring through devices and sensors have been driving the adoption of decentralized trials after the pandemic. Home health services patients with physical disabilities and restricted access due to location can promote retention in clinical trials. Partnering with home health service providers supported by nurses trained in use of portable equipment will facilitate smooth DCT implementation. Additionally, CROs are focused on innovating trial enrollment and patient engagement strategies by exploring multiple channels, such as use of advocacy groups, social media, and online physician referral systems.
Key Topics Covered:
1. Strategic Imperatives
- Why Is It Increasingly Difficult to Grow?
- The Strategic Imperative 8
- The Impact of the Top 3 Strategic Imperatives on the Global Decentralized Clinical Trial (DCT) Industry
- Growth Opportunities Fuel the Growth Pipeline Engine
2. Growth Opportunity Analysis, Decentralized Clinical Trials Market
- Definition: Evolving Clinical Trial Models
- Scope of Analysis and Segmentation
- COVID-19 Impact on the Clinical Trials Industry
- Key Growth Metrics for DCT Market
- Vendor Ecosystem for DCT Market
- Competitive Trends
- Growth Drivers for DCT Market
- Growth Restraints for DCT Market
3. Key Trends, DCT Market
- Regulatory Trends, Global DCT Market
- Business Model Trend, Global DCT Market
- Partnership Trends, Global DCT Market
- Key Investments Trends, Global DCT Market
- M&A Trends, Global DCT Market
- Forecast Assumptions, DCT Market
- Revenue Forecast, DCT Market
- Forecast Discussion, Global DCT Market
- Revenue Forecast by Region, DCT Market
- Revenue Forecast Analysis by Region, DCT Market
4. Growth Opportunity Universe, Decentralized Clinical Trials Market
- Growth Opportunity 1: Cloud-based Platform to Achieve Scalability and Workflow Standardization, 2021
- Growth Opportunity 2: At-home Patient Monitoring for Infectious Disease Trials, 2021
- Growth Opportunity 3: Omni-channel Recruitment to Expand Patient Reach and Ensure Diversity, 2021
5. Next Steps
- Your Next Steps
- List of Exhibits
- Legal Disclaimer
For more information about this report visit https://www.researchandmarkets.com/r/dnl4tg
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900